Welcome to the April 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we’re excited to share with you our new roundtable panel discussion, “Management of Myeloproliferative Neoplasms: A Case-Based Discussion.” I am joined by three expert colleagues as we highlight the current state of MPN treatment and management. We take you through three distinct cases covering myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET), with discussion and input from different perspectives within the health care team—the oncologist, the pharmacist, and the nurse practitioner.
As a companion to the panel discussion video, we’ve created “fast facts” guides detailing the incidence and mortality and the World Health Organization diagnostic criteria for MF, PV, and ET. We hope you find them to be a helpful and informative reference in your practice.
And we’re not done yet! In this month’s newsletter, we explore data from trials studying potential MPN treatments involving ruxolitinib, metformin, stem cell transplant, and pacritinib. We also highlight recently published journal articles exploring the emotional and financial impacts of myelofibrosis, the profile of Belgian patients with PV, and the role of Sipa1 deficiency in MPNs.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus